Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Analysis of extracorporeal photopheresis within the frame of the WAA register

Blaha, M. ; Gasova, Z. ; Berlin, G. LU ; Audzijoniene, J. ; Griskevicius, A. ; Dykes, J. LU ; Bhuiyanova, Z. ; Lanska, M. ; Eich, T. and Vrielink, H. , et al. (2021) In Transfusion and Apheresis Science 60(5).
Abstract

The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL). Material and method: 560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3−81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed. Results: Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were... (More)

The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL). Material and method: 560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3−81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed. Results: Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were registered in 5.4 % of the first treatments and in 1.2 % of the subsequent procedures. Severe AEs were present in 0.04 % of all procedures. No patient died due to the procedure. Tingling and stitching were the most common AE. For those with GVHD an improvement was noticed within approximately 10 procedures of ECP in the severity stage, QoL (from a mean of 6.1 to 6.8, p < 0.002) and the HC (6.1 -> 6.4, p < 0.014) and improved further with added procedures. Conclusion: Photopheresis is an established therapy with few side effects. The present study of soft variables indicate that GVHD shows benefits upon ECP within approximately 10 procedures in regard to the severity of mainly skin GVHD, and lower baseline levels of HC and QoL.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adverse events, Apheresis, Extracorporeal photopheresis, Graft versus host disease, Health criteria, Quality of life
in
Transfusion and Apheresis Science
volume
60
issue
5
article number
103172
publisher
Elsevier
external identifiers
  • scopus:85106976289
  • pmid:34059472
ISSN
1473-0502
DOI
10.1016/j.transci.2021.103172
language
English
LU publication?
yes
id
e62df042-aff9-452e-bbec-a227e0ca6383
date added to LUP
2021-12-27 15:17:21
date last changed
2025-01-13 20:39:57
@article{e62df042-aff9-452e-bbec-a227e0ca6383,
  abstract     = {{<p>The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL). Material and method: 560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3−81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed. Results: Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were registered in 5.4 % of the first treatments and in 1.2 % of the subsequent procedures. Severe AEs were present in 0.04 % of all procedures. No patient died due to the procedure. Tingling and stitching were the most common AE. For those with GVHD an improvement was noticed within approximately 10 procedures of ECP in the severity stage, QoL (from a mean of 6.1 to 6.8, p &lt; 0.002) and the HC (6.1 -&gt; 6.4, p &lt; 0.014) and improved further with added procedures. Conclusion: Photopheresis is an established therapy with few side effects. The present study of soft variables indicate that GVHD shows benefits upon ECP within approximately 10 procedures in regard to the severity of mainly skin GVHD, and lower baseline levels of HC and QoL.</p>}},
  author       = {{Blaha, M. and Gasova, Z. and Berlin, G. and Audzijoniene, J. and Griskevicius, A. and Dykes, J. and Bhuiyanova, Z. and Lanska, M. and Eich, T. and Vrielink, H. and Witt, V. and Seval, G. C. and Ilhan, O. and Stegmayr, B.}},
  issn         = {{1473-0502}},
  keywords     = {{Adverse events; Apheresis; Extracorporeal photopheresis; Graft versus host disease; Health criteria; Quality of life}},
  language     = {{eng}},
  number       = {{5}},
  publisher    = {{Elsevier}},
  series       = {{Transfusion and Apheresis Science}},
  title        = {{Analysis of extracorporeal photopheresis within the frame of the WAA register}},
  url          = {{http://dx.doi.org/10.1016/j.transci.2021.103172}},
  doi          = {{10.1016/j.transci.2021.103172}},
  volume       = {{60}},
  year         = {{2021}},
}